11 completed. 4 Phase 1, 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow CSL Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of in Vitro Blocking the Common Beta Chain on Cell Viability in Asthma Allergen - Asthma | Completed | Hamilton Health Sciences Corporation | 10 | 2012-11-01 | 2017-07-13 | |
| A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission CSL362 - Leukemia, Myeloid, Acute | Phase 1 | Completed | CSL Limited | 30 | 2012-07-01 | 2015-10-09 |
| A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients CSL112 (reconstituted high density lipoprotein), Placebo - Stable Atherothrombotic Disease | Phase 2 | Completed | CSL Limited | 45 | 2012-02-01 | 2014-02-06 |
| A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers CSL112, Placebo - Healthy | Phase 1 | Completed | CSL Limited | 36 | 2011-01-01 | 2012-03-07 |
| Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers CSL112 (reconstituted HDL), normal saline (0.9%) - Healthy | Phase 1 | Completed | CSL Limited | 57 | 2010-06-01 | 2011-01-24 |
| Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency Immunoglobulin G (Ig NextGen 16%) - Primary Immune Deficiency | Phase 3 | Completed | CSL Limited | 41 | 2008-04-01 | 2013-06-19 |
| Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients IgNextGen 10% - Idiopathic Thrombocytopenic Purpura (ITP) | Phase 3 | Completed | CSL Limited | 19 | 2007-06-01 | 2016-07-18 |
| Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) IntragamP, Ig NextGen 10% - Primary Immune Deficiency (PID) | Phase 3 | Completed | CSL Limited | 19 | 2007-05-01 | 2012-06-07 |
| Subcutaneous Ig NextGen 16% in PID Patients IgNextGen 16% - Primary Immunodeficiency (PID) | Phase 3 | Completed | CSL Limited | 35 | 2007-04-01 | 2012-06-07 |
| Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia CSL360 - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | CSL Limited | 40 | 2006-12-01 | 2009-09-16 |
| Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL rHDL - Acute Coronary Syndromes | Phase 2 | Completed | CSL Limited | 180 | 2005-07-01 | 2008-11-10 |
Primary Immunodeficiency Diseases (3) · Leukemia, Myeloid, Acute (2) · Acute Coronary Syndrome (1) · Asthma (1) · Hemorrhage (1) · Purpura, Thrombocytopenic, Idiopathic (1)
CSL112 (3) · Allergens (1) · CSL360 (1) · Immunoglobulin G (1) · Saline Solution (1)
Australia (8) · Canada (2) · New Zealand (2) · United States (2)
Andrew Roberts, Dr (1) · Dr. Denise D'Andrea (1) · Dr. Mark DeWitte (1) · Gail M Gauvreau, PhD (1) · Jean-Claude Tardif, MD FRCP (1) · Karl Bleasel, Dr (1) · Marianne Empson, Dr (1)
PMID 33217027, PMID 17387133, PMID 22212346, PMID 22526590, PMID 24122814, PMID 26307570